<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00187915</url>
  </required_header>
  <id_info>
    <org_study_id>CEL330</org_study_id>
    <secondary_id>20030499</secondary_id>
    <nct_id>NCT00187915</nct_id>
  </id_info>
  <brief_title>Pilot Trial for Implementation of a MPA PK Monitoring Strategy</brief_title>
  <acronym>MPA</acronym>
  <official_title>Pilot Trial for Implementation of a MPA PK Monitoring Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective interventional trial of de novo renal transplant recipients,
      aiming to validate a strategy which combines the use of early post transplant MPA AUC
      sampling, and subsequent MPA trough level monitoring to implement MPA PK monitoring in a
      clinically applicable fashion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mycophenolate mofetil or MMF (CellCept® by Roche) is the mofetil ester of mycophenolic acid
      (MPA), the active immunosuppressant.

      MMF significantly decreases the episodes of acute rejection in kidney transplant patients;
      but as with any medication without adequate pharmacokinetic drug monitoring, the issue of
      under or over immunosuppression arises. For this reason, the biggest challenge lies with
      establishing a feasible mean of MPA pharmacokinetic monitoring. Thus far no study has shown
      that measuring MPA trough levels alone correlates with rejection, unlike MPA Area Under the
      concentration time Curve (AUC), due to the large incidence of inter- and intra-patient
      variability.

      This is the first prospective blinded trial set up to analyze the correlation between
      individualized MPA AUC and trough levels of kidney transplant patients in hopes of
      establishing a more efficacious way of monitoring MPA. MPA target trough levels that
      correspond to AUC greater than 30 mg x h/L could then be utilized as maintenance
      measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with an average AUC between 30-60 ng x hr/mL</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute rejection of transplanted kidney</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of MPA related toxicities</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dose changes required to obtain MPA AUC target in the first month</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Transplant, Kidney</condition>
  <arm_group>
    <arm_group_label>CellCept + Prograf</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care Regime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CellCept + Neoral</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of Care Regime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil + Tacrolimus</intervention_name>
    <description>Target MPA exposure to 30-60 mg/L/h during first month post-transplant</description>
    <arm_group_label>CellCept + Prograf</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
    <other_name>Ro 70-0003</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil + Cyclosporin</intervention_name>
    <description>Target MPA exposure to 30-60 mg/L/h during first month post-transplant</description>
    <arm_group_label>CellCept + Neoral</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
    <other_name>RO 70-0003</other_name>
    <other_name>Neoral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary or secondary cadaveric or living donor kidney recipients

          -  On Cellcept

        Exclusion Criteria:

          -  Multi organ recipients

          -  Documented non-compliance

          -  Not on a calcineurin inhibitor

          -  GFR &lt;25 ml/min by Cockcroft Gault equation

          -  Serum albumin &lt;2.5 mg/dl

          -  Pregnant

          -  Active serious digestive disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herwig-Ulf Meier-Kriesche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995 May 27;345(8961):1321-5.</citation>
    <PMID>7752752</PMID>
  </reference>
  <reference>
    <citation>Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995 Aug 15;60(3):225-32.</citation>
    <PMID>7645033</PMID>
  </reference>
  <reference>
    <citation>A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996 Apr 15;61(7):1029-37.</citation>
    <PMID>8623181</PMID>
  </reference>
  <reference>
    <citation>Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant. 2003 Jan;3(1):68-73.</citation>
    <PMID>12492713</PMID>
  </reference>
  <reference>
    <citation>Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation. 2003 Apr 27;75(8):1341-6.</citation>
    <PMID>12717227</PMID>
  </reference>
  <reference>
    <citation>Hale MD, Nicholls AJ, Bullingham RE, Hené R, Hoitsma A, Squifflet JP, Weimar W, Vanrenterghem Y, Van de Woude FJ, Verpooten GA. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998 Dec;64(6):672-83.</citation>
    <PMID>9871432</PMID>
  </reference>
  <reference>
    <citation>van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999 Jul 27;68(2):261-6.</citation>
    <PMID>10440399</PMID>
  </reference>
  <reference>
    <citation>van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation. 2005 Oct 15;80(2 Suppl):S244-53. Review.</citation>
    <PMID>16251857</PMID>
  </reference>
  <reference>
    <citation>Shaw LM, Mick R, Nowak I, Korecka M, Brayman KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998 Mar;38(3):268-75.</citation>
    <PMID>9549665</PMID>
  </reference>
  <reference>
    <citation>van Gelder T, Klupp J, Barten MJ, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001 Apr;23(2):119-28.</citation>
    <PMID>11294511</PMID>
  </reference>
  <reference>
    <citation>Srinivas TR, Meier-Kriesche HU, Kaplan B. Pharmacokinetic principles of immunosuppressive drugs. Am J Transplant. 2005 Feb;5(2):207-17.</citation>
    <PMID>15643980</PMID>
  </reference>
  <reference>
    <citation>Yamani MH, Starling RC, Goormastic M, Van Lente F, Smedira N, McCarthy P, Young JB. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection. Transplantation. 2000 Jun 15;69(11):2326-30.</citation>
    <PMID>10868634</PMID>
  </reference>
  <reference>
    <citation>Shaw LM, Pawinski T, Korecka M, Nawrocki A. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit. 2002 Feb;24(1):68-73. Review.</citation>
    <PMID>11805725</PMID>
  </reference>
  <reference>
    <citation>Mourad M, Wallemacq P, König J, de Frahan EH, Eddour DC, De Meyer M, Malaise J, Squifflet JP. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet. 2002;41(5):319-27. Review.</citation>
    <PMID>12036390</PMID>
  </reference>
  <reference>
    <citation>Cattaneo D, Perico N, Gaspari F, Gotti E, Remuzzi G. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int. 2002 Sep;62(3):1060-7.</citation>
    <PMID>12164891</PMID>
  </reference>
  <reference>
    <citation>Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003 May;3(5):534-42. Review.</citation>
    <PMID>12752309</PMID>
  </reference>
  <reference>
    <citation>Cattaneo D, Gaspari F, Ferrari S, Stucchi N, Del Priore L, Perico N, Gotti E, Remuzzi G. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant. 2001 Dec;15(6):402-9.</citation>
    <PMID>11737117</PMID>
  </reference>
  <reference>
    <citation>Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002 Oct 27;74(8):1070-6.</citation>
    <PMID>12438948</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>October 19, 2011</last_update_submitted>
  <last_update_submitted_qc>October 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal transplant</keyword>
  <keyword>Cellcept</keyword>
  <keyword>Therapeutic drug level</keyword>
  <keyword>Mycophenolate mofetil (MMF)</keyword>
  <keyword>Mycophenolate Acid (MPA)</keyword>
  <keyword>Oral Bioavailability</keyword>
  <keyword>Immunosuppression</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

